On "Composition, Quality Control, and Labeling of Plasma-Derived Products for the Treatment of von Willebrand disease" (Semin Thromb Hemost 2006;32: 529-536).
Svae
Tor-Einar
TE
Biesert
Lothar
L
Neisser-Svae
Andrea
A
Kannicht
Christoph
C
Römisch
Jürgen
J
D016913:Blood Component Transfusion / Q000009:adverse effects / Q000592:standards*; D006801:Humans; D011786:Quality Control; D038301:Virus Inactivation; D014842:von Willebrand Diseases / Q000150:complications / Q000628:therapy*